PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine
Authors
Keywords
-
Journal
OncoImmunology
Volume 5, Issue 8, Pages e1202391
Publisher
Informa UK Limited
Online
2016-07-02
DOI
10.1080/2162402x.2016.1202391
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies
- (2015) Troels H. Borch et al. DRUG DISCOVERY TODAY
- Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy
- (2015) M. H. Andersen JNCI-Journal of the National Cancer Institute
- Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy
- (2015) M. H. Andersen JNCI-Journal of the National Cancer Institute
- The targeting of immunosuppressive mechanisms in hematological malignancies
- (2014) M H Andersen LEUKEMIA
- Attenuation of IFN-γ-induced B7-H1 expression by 15-deoxy-delta12,14-prostaglandin J2 via downregulation of the Jak/STAT/IRF-1 signaling pathway
- (2014) Su-Kil Seo et al. LIFE SCIENCES
- HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients
- (2013) S. Munir et al. CANCER RESEARCH
- Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells
- (2013) S Munir et al. LEUKEMIA
- Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway
- (2013) S M Ahmad et al. LEUKEMIA
- The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+T cells
- (2013) Shamaila Munir et al. OncoImmunology
- Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells
- (2012) E. F. Tewalt et al. BLOOD
- Cellular Based Cancer Vaccines: Type 1 Polarization of Dendritic Cells
- (2012) M. Hansen et al. CURRENT MEDICINAL CHEMISTRY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of heme oxygenase-1–specific regulatory CD8+ T cells in cancer patients
- (2009) Mads Hald Andersen et al. JOURNAL OF CLINICAL INVESTIGATION
- Molecular Antagonism and Plasticity of Regulatory and Inflammatory T Cell Programs
- (2008) Xuexian O. Yang et al. IMMUNITY
- Th17 cells: a new fate for differentiating helper T cells
- (2008) Zhi Chen et al. IMMUNOLOGIC RESEARCH
- Therapeutic Dendritic Cell Vaccination of Patients With Metastatic Renal Cell Carcinoma
- (2008) Annika Berntsen et al. JOURNAL OF IMMUNOTHERAPY
- PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients
- (2008) T Kozako et al. LEUKEMIA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More